Sangamo BioSciences | SGMO - Equity Capital And Reserves


Sangamo BioSciences reported $19.6M in Equity Capital and Reserves for its fiscal quarter ending in June of 2025.





Equity Capital And Reserves Change Date
Alaunos Therapeutics USD 2.8M 858K Sep/2025
Alnylam Pharmaceuticals USD 233.89M 16.7M Sep/2025
Alterity Therapeutics Limited AUD 22.81M 5.29M Jun/2023
Amgen USD 9.62B 2.19B Sep/2025
Bayer EUR 29.7B 799M Sep/2025
BioCryst Pharmaceuticals USD -387.89M 33.7M Sep/2025
Biogen USD 18.21B 573.5M Sep/2025
BioMarin Pharmaceutical USD 6.06B 29.6M Sep/2025
Cipla INR 329.19B 16.3B Sep/2025
Clal Biotechnology ILS 121.41M 4.62M Dec/2023
Compugen USD 43.83M 6.43M Sep/2025
CSL USD 21.41B 861M Jun/2025
Gilead Sciences USD 22.62B 1.16B Dec/2025
GlaxoSmithKline GBP 16.38B 229M Dec/2025
Grifols EUR 6.08B 34.72M Sep/2025
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
J&J USD 78.47B 0 Sep/2025
Karyopharm Therapeutics USD -269.26M 30.33M Sep/2025
Merck USD 51.85B 2.79B Sep/2025
Novartis USD 44.75B 2.7B Sep/2025
Omeros USD -228.68M 15.13M Jun/2025
Pfizer USD 92.8B 4.11B Sep/2025
Roche Holding CHF 33.8B 758M Dec/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Sanofi EUR 71.71B 1.55B Dec/2025
Sarepta Therapeutics USD 1.32B 37.26M Sep/2025
Tectonic Therapeutic USD 267.53M 16.24M Sep/2025
Ultragenyx Pharmaceutical USD 9.16M 142.13M Sep/2025
Vertex Pharmaceuticals USD 17.32B 143.4M Sep/2025